The circulating microRNA-221 level in patients with malignant melanoma as a new tumor marker
The circulating microRNA-221 level in patients with malignant melanoma as a new tumor marker
复制标题
DOI：
10.1016/j.jdermsci.2010.12.010
复制
发表时间：
2011-03-01
影响因子：
4.6
通讯作者：
Ihn, Hironobu
中科院分区：
文献类型：
--
作者：
Kanemaru, Hisashi;Fukushima, Satoshi;Ihn, Hironobu
背景资料：已知microRNA-221（miR-221）在恶性黑素瘤（MM）细胞中异常表达，并且其通过下调p27 Kip 1/CDKN 1B和c-KIT受体而有利于恶性表型的诱导。目的：探讨血清miR-221水平作为多发性骨髓瘤（MM）的一个标志物的可能性。从血清中纯化microRNA，并通过定量实时聚合酶链反应测定miR-221水平。MM患者的miR-221水平显著高于健康对照。在MM患者中，与原位MM患者相比，I-IV期MM患者的miR-221水平显著升高，并且该水平与肿瘤厚度相关。此外，一项纵向研究显示，手术切除原发性肿瘤后，miR-221水平呈下降趋势，复发时再次升高。在MM患者中，血清miR-221水平显著升高，不仅可用于MM的诊断，而且可用于原位区分MM与I-IV期MM，以及用于在随访期间评估肿瘤进展和监测患者。此外，考虑到miR-221的血清水平与肿瘤厚度相关，miR-221也可能用作MM患者的预后标志物。（C）2011日本皮肤病研究学会。由Elsevier爱尔兰有限公司出版。保留所有权利。
Background: MicroRNA-221 (miR-221) is known to be abnormally expressed in malignant melanoma (MM) cells, and it favors the induction of the malignant phenotype through down-modulation of p27Kip1/CDKN1B and the c-KIT receptor. This suggests that the serum level of miR-221 might increase in patients with MM and thus could be used as a new tumor marker.Objective: To evaluate the possibility that the serum miR-221 level can be a marker of MM.Methods: Serum samples were obtained from 94 MM patients and 20 healthy controls. MicroRNAs were purified from serum, and miR-221 levels were measured by quantitative real-time polymerase chain reaction.Results: Circulating miR-221 was detectable and could be quantified in serum samples. MM patients had significantly higher miR-221 levels than healthy controls. Among the MM patients, the miR-221 levels were significantly increased in patients with stage I-IV MM compared to those with MM in situ, and the levels were correlated with tumor thickness. Moreover, a longitudinal study revealed a tendency for the miR-221 levels to decrease after surgical removal of the primary tumor, and to increase again at recurrence.Conclusions: Serum levels of miR-221 were significantly increased in MM patients and may be useful not only for the diagnosis of MM, but also for the differentiating MM in situ from stage I-IV MM, and for evaluating tumor progression and monitoring patients during the follow-up period. In addition, considering that the serum levels of miR-221 were correlated with tumor thickness, miR-221 might also be useful as a prognostic marker for patients with MM. (C) 2011 Japanese Society for Investigative Dermatology. Published by Elsevier Ireland Ltd. All rights reserved.